Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium

2017 ◽  
Vol 523 (1) ◽  
pp. 343-356 ◽  
Author(s):  
Daoqi Luo ◽  
Joo Hee Kim ◽  
Chulhun Park ◽  
Euichaul Oh ◽  
Jun-Bom Park ◽  
...  
Keyword(s):  
Physicochemical Characterization ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Pravastatin Sodium ◽  
Bilayer Tablet ◽  
Dose Combination ◽  
Enteric Coated

scholarly journals Isolation, Identification and Characterization of Degradation Impurity of Atorvastatin in Fixed Dose Combination of Atorvastatin and Ezetimibe

2019 ◽  
Vol 11 (05) ◽  
Author(s):  
Rajesh Desai ◽  
Suresh Koradia
Keyword(s):  
Reversed Phase ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Forced Degradation ◽  
Preparative Hplc ◽  
Atorvastatin Calcium ◽  
Isolation And Characterization ◽  
Dose Combination ◽  
Liquid Chromatographic

The objective of this study is to isolation and characterization of unknown degradation product of Atorvastatin calcium in combination formulation product with Ezetimibe by using modern techniques of separation and aracterization. An unknown impurity is generating during a forced degradation study of Atorvastatin and Ezetimibe fixed-dose combination tablets. By using the gradient reversed-phase high-pressure liquid chromatographic method, unknown degradation impurity was detected and quantified in the range of 0.05% to 0.2% of Atorvastatin. The impurity was enriched by extreme oxidation degradation of Atorvastatin and isolated through preparative HPLC. The structure of the impurity was characterized by mass and NMR spectrum.

Cocrystals of zonisamide: physicochemical characterization and sustained release solid forms

CrystEngComm ◽  
2018 ◽  
Vol 20 (21) ◽  
pp. 2923-2931 ◽  
Author(s):  
Srinivasulu Aitipamula ◽  
Joseph Cadden ◽  
Pui Shan Chow
Keyword(s):  
Sustained Release ◽  
Physicochemical Characterization ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Combination Drug ◽  
Dose Combination ◽  
Treatment Of Obesity ◽  
Obesity Drugs

A multi-API cocrystal containing two anti-obesity drugs, zonisamide and caffeine, was found to be promising for the development of a sustained release fixed-dose combination drug for the treatment of obesity.

Sign in / Sign up

Export Citation Format

Share Document